Pharma BD Deal Intelligence
DPC gave Siemens immunodiagnostics scale, but the diagnostics roll-up it anchored took a €1.4B impairment and never became the growth engine promised.
Full analysis, sources & comparables →BioSpace highlighted DPC's IMMULITE franchise and 100-country footprint as the platform foundation Siemens needed to enter immunodiagnostics against Roche and…
Siemens agreed to acquire DPC at $58.50/share cash (~$1.86B) to enter in vitro diagnostics with the IMMULITE immunoassay platform.
Siemens offered $58.50 per share, a 21% premium over the previous trading day; Diagnostic Products shares jumped 19% to $57.81. The purchase gives Siemens an…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Siemens acquired Diagnostic Products Corporation for $58.50 per share in cash, approximately $1.86 billion (a roughly 21% premium), to enter the in vitro diagnostics market via DPC's IMMULITE immunoassay platform and 100-country commercial footprint. The deal gave Siemens an immediate foothold in immunodiagnostics against incumbents Roche and Abbott and was paired months later with Siemens' acquisition of Bayer Diagnostics to build an integrated diagnostics business.
DPC gave Siemens immunodiagnostics scale, but the diagnostics roll-up it anchored took a €1.4B impairment and never became the growth engine promised.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Siemens AG / Diagnostic Products Corporation (this deal) | 2006 | $1.9B | 48 |
| Siemens AG / Bayer Diagnostics | 2006 | $5.4B | 38 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals